VALENCIA, SPAIN--(Marketwired - May 21, 2014) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that based on data and information provided by and reviews with Zenon Biosystem considerable progress has been made since signing the development agreement six months ago.
Development of the Company's MRSA device commenced in December, 2013. A technical review of Volatile Organic Compounds ("VOCs") produced by Methicillin-susceptible S.aureus ("MSSA") and MRSA in vitro or exhaled breath was undertaken. Several compounds, including compounds that might be used to discriminate between MRSA and MSSA, were identified as having potential utility to identify S. aureus ("SA") from background VOCs produced by smoking and natural flora.
A comprehensive work plan and laboratory protocols were established using Gold Standard Gas Chromatography/Mass Spectrometry techniques ("GC/MS") and Solid Phase Micro Extraction ("SPME") and the following testing has been successfully carried out;
- Identifying the target VOCs in the headspace above a contained bacterial culture;
- Correlating target VOCs with exhaled breath in infected patients with SA; and
- Detecting those VOCs with an appropriate gas sensor.
An in-depth review has also been carried out to determine suitable gas sensors. These sensors fall into two broad groups, Metal Oxide ("MO") sensors and polymer based sensors. Several different sensors of each type have been subjected to both numerous in vitro headspace tests and exhaled breath tests using an optimised SPME fiber VOC collection, to determine detection limits and therefore suitability. In addition, a cost effective exhaled breath collection technique and protocol has been developed to assist the correlation process.
These initial tests using basic MO sensors have assessed the response to MSSA and MRSA in headspace and exhaled breath in 14 volunteers (6 SA carriers and 8 non-carriers). The principal component analysis indicated a sensibility and specificity of as high as 75% and 66% respectively.
Work is underway with the intention of increasing the sensibility and specificity by a multiple of up to 10 using a new design Surface Acoustic Wave multiple polymer sensor. These sensors are also low cost, of high sensitivity and stability, and have a low power consumption compared to MO sensors.
In parallel, there has been significant development of the complex algorithmic processing to reduce interference from unrelated VOCs and to amplify the detection of SA specific signature VOCs. Data obtained from the GC/MS testing continues to be analysed to identify additional SA compounds which might be used to detect the presence of MSSA and MRSA in exhaled breath.
The next steps will be to commence laboratory experiments with coagulase-negative Staphylococci strains and hospital experiments with clinical MRSA, MSSA and coagulase-negative Staphylococci strains.
During the period collaboration agreements and partnerships have been established with relevant hospitals, universities and a private laboratory in the various fields of sensors, polymer electrochemistry, microbiology, infectious disease, pneumology, chromatography and microorganism identification.
About Zenosense, Inc.
Zenosense, Inc. is a detection device development company based in Valencia, Spain. Its mission is develop, market and sell an effective MRSA detector, by way of licenced-in technology, for sale to healthcare providers for use in clinical settings. The Company believes there is enormous latent demand for a cost-effective MRSA detector, driven by the costs associated with the late detection of MRSA, and that it has identified a valuable new market segment for a wearable detection device. The development and exclusive license agreement also includes cancer sensory devices. Find out more at www.zenosense.net.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed on filed on March 26, 2014, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Statements concerning the development of the MRSA detector have been made based on information obtained from Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.